# EDGAR Filing Document

**Accession Number:** 0001084201
**File Stem:** 0001213900-25-054408
**Filing Date:** 2025-6
**Character Count:** 25590
**Document Hash:** dba0eea9807fbc5492fc9cad83e39231
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-054408.hdr.sgml**: 20250613

**ACCESSION NUMBER**: 0001213900-25-054408

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250613

**DATE AS OF CHANGE**: 20250613

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SINOVAC BIOTECH LTD
- **CENTRAL INDEX KEY:** 0001084201
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** B9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-79318
- **FILM NUMBER:** 251048010

**BUSINESS ADDRESS:**
- **STREET 1:** NO. 39 SHANGDI XI ROAD
- **STREET 2:** HAIDIAN DISTRICT
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 100085
- **BUSINESS PHONE:** 86-10-82890088

**MAIL ADDRESS:**
- **STREET 1:** NO. 39 SHANGDI XI ROAD
- **STREET 2:** HAIDIAN DISTRICT
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 100085

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NET FORCE SYSTEMS INC
- **DATE OF NAME CHANGE:** 19991110
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vivo Capital VIII, LLC
- **CENTRAL INDEX KEY:** 0001618789

**ORGANIZATION NAME:**
- **EIN:** 471761992
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** 650 688 0822

**MAIL ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301

## Ex-99.J

**Exhibit J**

Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company's False and Misleading Claims

 

*Affirms Support for Fair and Equitable Dividend Distribution for All Shareholders by Sinovac* 

 

*Corrects the Company's Misrepresentations of Vivo's Capital Contributions, Which Have Been Critical to Sinovac's Commercial Success and Ability to Return Capital to Shareholders*

 

*Calls on All Shareholders to Stand up for Transparent Corporate Governance and Elect Qualified Directors to the Board at Upcoming Special Meeting on July 8*

 

PALO ALTO, Calif.--(BUSINESS WIRE)--Vivo Capital ("Vivo" or "we"), a leading global investment firm focused exclusively on healthcare and life sciences and an approximately 8% shareholder in Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), today sent a letter to shareholders.

\*\*\*

Dear Fellow Sinovac Shareholders,

We, Vivo Capital ("Vivo"), write to you as fellow shareholders of Sinovac Biotech Ltd. ("Sinovac" or the "Company") to address a number of statements in the April 29, 2025 letter from Sinovac's Board of Directors (the "Board") that we believe are false, and to reaffirm our commitment to upholding the best interests of all shareholders and to transparent corporate governance.

The Board has deceptively portrayed recent events as centering around a dispute with Vivo only. But the problem is at Sinovac's Board, not at Vivo. In fact, Sinovac's Board has precipitated a corporate governance crisis that threatens the Company's future growth and has eroded its credibility with all shareholders. After the Privy Council ruled in January that five (5) directors had been elected in February 2018 consistent with Antiguan law, a new Board was installed—but contrary to the claims of the Board, its composition did not match the slate the Privy Council had considered. With no transparency, multiple directors have purportedly resigned and been replaced within three months, casting substantial uncertainty over the Company's corporate governance and stability. Further, the Company's independent auditor, Grant Thornton Zhitong Certified Public Accountants LLP, resigned in response to the Board's April 1, 2025 statement that attempted to cast doubt on the validity of the Company's corporate actions over the past seven years.<sup>1</sup> This resignation, in turn, prompted Sinovac's own management to publicly express concerns that the current Board's actions have disrupted Sinovac's compliant operations and governance.<sup>2</sup>

Further, dissatisfaction with the current Board does not just come from Vivo. Another major shareholder, SAIF Partners, formally requisitioned a special meeting of shareholders, which will be held on July 8, to elect new directors to the Board.<sup>3</sup>

<sup>1</sup> Sinovac's Form 6-K filed with the U.S. Securities and Exchange Commission (the "SEC") dated April 21, 2025, available at https://www.sec.gov/Archives/edgar/data/1084201/000110465925036821/tm2512765d1_6k.htm.

<sup>2</sup> Press Release, Sinovac Management Statement Regarding Auditor Resignation, available at: https://www.globenewswire.com/news-release/2025/04/22/3065123/0/en/SINOVAC-Management-Statement-Regarding-Auditor-Resignation.html.

<sup>3</sup> SAIF Partners IV L.P.'s Schedule 13D filed with the SEC, available at: https://www.sec.gov/Archives/edgar/data/1084201/000110465925041188/xslSCHEDULE_13D_X01/primary_doc.xml.

In its April 29 letter, the Board continued its attempts to rewrite the Company's history. As shareholders, you will have an important decision regarding the future of your investment—so we want to ensure you have the accurate information regarding these matters:

&nbsp;&nbsp;&nbsp;&nbsp;1.  **<u>Vivo supports the distribution of dividends.</u>** The Board's suggestion that Vivo aims
to prevent shareholders from receiving dividends is false. As an investment firm, we fully expect the Company to distribute excess cash
to all shareholders, including ourselves, as we are committed to fulfilling our fiduciary duties to our limited partners by seeking timely
investment returns. However, the Board must ensure that any dividend payments are made lawfully and equitably, to the benefit of all shareholders,
rather than by excluding long-time shareholders like Vivo for the personal benefit of individual Board members.

&nbsp;&nbsp;&nbsp;&nbsp;2.  **<u>Vivo has never controlled the Company's Board.</u>** Since our PIPE investment in July 2018,
Vivo has held approximately 8% of the Company's shares and has had only one representative on its six-seat Board. Contrary to the
current Board's statement, Vivo has never sought nor possessed control of the Board or the Company. 1Globe and OrbiMed, on the other
hand, who have now sued Vivo and another investor in Antigua, fully control the current Board with three purported seats held by directors
of their choosing, two of whom were not on the slate proposed at the Annual General Meeting in February 2018 (the "AGM"),
despite holding only a minority interest.

&nbsp;&nbsp;&nbsp;&nbsp;3.  **<u>1Globe's war against the Company directly led to NASDAQ trading halt.</u>** The Board has claimed
 that Vivo controlled the former Board and caused the NASDAQ trading halt. This is also false.
 The former Board was in place before Vivo's initial investment in the Company, which
 occurred six months after 1Globe ambushed the AGM. 1Globe subsequently launched a prolonged
 legal battle against the Company. As a result of the 1Globe litigation, the trading of Sinovac's
 stock was halted in February 2019. The recent resignation of the independent auditor has
 resulted in Sinovac's inability to timely file its annual report with the SEC, <sup>4</sup> which in turn led to a notification
 of non-compliance from the NASDAQ. <sup>5</sup> The
 Company is required to submit a plan to regain compliance by July 15, 2025 and may risk being
 delisted if the plan is not accepted by the NASDAQ.

&nbsp;&nbsp;&nbsp;&nbsp;4.  **<u>Vivo made its PIPE investment in good faith, responding to the Company's financial needs.</u>** Vivo invested in Sinovac in July 2018, when the Company needed capital to launch two vaccine projects and to further develop its production
facility in Beijing. At that time, the Company lacked surplus cash reserves and was unable to secure additional bank financing due to
1Globe's litigation against the Company. It was under these circumstances that we invested in the Company through the PIPE—an
arm's length investment made in good faith.

<sup>4</sup> Sinovac's Form 12b-25 (Notification of Late Filings) filed with the SEC dated April 29, 2025, available at https://www.sec.gov/Archives/edgar/data/1084201/000110465925041192/tm2512765d2_nt20f.htm.

<sup>5</sup> Sinovac's Form 6-K filed with the SEC dated May 23, 2025, available at https://www.sec.gov/Archives/edgar/data/1084201/000110465925052180/tm2515927d1_6k.htm.

&nbsp;&nbsp;&nbsp;&nbsp;5.  **<u>Vivo's capital contributions were critical to successful development and commercialization of COVID-19 vaccine.</u>** At the beginning of 2020, Sinovac's Beijing operating entity Sinovac Life Sciences Co., Ltd. ("SLS")
was in a dire situation, as the capital required for the development and production of CoronaVac far exceeded its available funds. Vivo
aided in at least three ways:

● <u>First,</u> the cash injection from the PIPE investment enabled Sinovac to provide approximately $24 million in total to SLS for CoronaVac's development.

● <u>Second,</u> when 1Globe's protracted lawsuit led to the NASDAQ trading halt and prevented Sinovac from securing additional financing, Vivo and its co-investor each provided $7.5 million to SLS through a convertible bond structure in May 2020, ensuring the successful completion of CoronaVac's clinical trials. Vivo made this investment notwithstanding the significant uncertainties around CoronaVac's viability and profitability as it had not even completed its Phase I clinical trial at that time.

● <u>Third,</u> Vivo introduced additional investors to SLS, who subsequently provided $527 million of much-needed additional capital for ramping up CoronaVac's production at the end of 2020. SLS enjoyed a higher valuation in this round, because by then China had approved CoronaVac's emergency use, Phase III clinical trials were underway globally, a key production facility had begun operations, and the Company had received vaccine purchase orders from customers.

Vivo's contributions were vital to the success of CoronaVac and have benefitted all shareholders. By contrast, 1Globe purchased all of its Sinovac shares from the open market without contributing a single dollar, or otherwise providing any support, to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;6.  **<u>There is no "double-dip" attempt by Vivo in receiving dividends.</u>** The Board misleadingly
asserted that Vivo intends to "double-dip" on dividends. As explained above, Vivo made two separate investments in the Company,
including the PIPE investment in the holding company and the convertible bond investment in SLS, both of which were essential in supporting
the success of the CoronaVac. These were arm's length transactions based on public trading price and/or independent third-party
fairness opinions. Although SLS has issued dividends (including dividends to Sinovac, the public parent company, proportionate to its
ownership), Vivo, like our fellow shareholders, has never received any dividend for its shareholding in the holding company.

The Board's recent actions, including its threat to invalidate the PIPE transaction notwithstanding 1Globe's inability to obtain such relief in seven years of litigation in Antigua, left Vivo with no choice but to initiate legal proceedings. Vivo is litigating not just to protect its own interests, but the interests of all shareholders. We are gravely concerned about the Board's improper actions which have directly undermined the Company's governance and precipitated the current crisis, as evidenced by the resignation of the Company's independent auditor, the Company's delayed filing of its annual report with the SEC, and its receipt of notification of non-compliance from the NASDAQ.

Our position is clear: all shareholders deserve to be treated fairly and equitably. Importantly, the Board's current actions risk harming all shareholders, as the Board's attempt to disenfranchise long-term shareholders like Vivo sets an alarming precedent of how it values and rewards key investors and how it views the legal and contractual obligations of the Company. Indeed, the Board is now attempting to illegally exclude Vivo and another long-term shareholder from the July 8 shareholders meeting. These actions would, among other things, make it harder for Sinovac to attract investors in the future, hurting the Company and all of its shareholders.

We urge all of our fellow shareholders to join us in helping to restore trust in the Company's governance. We appreciate your continued support as we work to ensure the Company's future is built on integrity, transparency, and respect for all stakeholders.

Sincerely,

Vivo Capital LLC

**About Vivo Capital**

Founded in 1996, Vivo Capital is a leading global healthcare investment firm with a diverse, multi-fund investment platform spanning venture capital, growth equity, buyout, and public equities. The Firm has approximately $5.3 billion in regulatory assets under management and has invested in over 430 public and private companies globally. Headquartered in Palo Alto, California, the Vivo team consists of more than 75 multi-disciplinary professionals. Vivo invests broadly in healthcare across multiple sub-sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets globally.

**Contacts**

Media<br> Pro-vivo@Prosek.com

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 5)**

**Sinovac Biotech Ltd.**

*(Name of Issuer)*

**Common Shares, $0.001 par value per share**

*(Title of Class of Securities)*

**P8696W104**

*(CUSIP Number)*

**Vivo Capital, LLC**<br>192 Lytton Avenue<br>Palo Alto CA 94301<br>650-688-0818

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/11/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **P8696W104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Vivo Capital VIII, LLC** | Name of reporting person<br>**Vivo Capital VIII, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1361236.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1361236.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1361236.00** | Aggregate amount beneficially owned by each reporting person<br>**1361236.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.9%** | Percent of class represented by amount in Row (11)<br>**1.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The beneficial ownership reported herein reflects that 1,196,073 of such shares are held by Vivo Capital Fund VIII, L.P. and 165,163 of such shares are held by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P.

The beneficial ownership percentage reported herein is based on 71,860,702 common shares outstanding as of March 31, 2024, as reported in the Issuer's Form 20-F filed with the Securities and Exchange Commission on April 29, 2024.

| **CUSIP No.** | **P8696W104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Vivo Capital IX, LLC** | Name of reporting person<br>**Vivo Capital IX, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4541764.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4541764.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4541764.00** | Aggregate amount beneficially owned by each reporting person<br>**4541764.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.3%** | Percent of class represented by amount in Row (11)<br>**6.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The beneficial ownership reported herein reflects that such shares are held by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

The beneficial ownership percentage reported herein is based 71,860,702 common shares outstanding as of March 31, 2024, as reported in the Issuer's Form 20-F filed with the Securities and Exchange Commission on April 29, 2024.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares, $0.001 par value per share

**(b) Name of Issuer:**
Sinovac Biotech Ltd.

**(c) Address of Issuer's Principal Executive Offices:**
No. 39 Shangdi Xi Road, Haidian District, Beijing, F4, 100085

Reference is hereby made to the statement on Schedule 13D filed with the Securities and Exchange Commission on July 11, 2018 by Vivo Capital, LLC with respect to the Common Shares, par value $0.001 per share ("Common Shares") of Sinovac Biotech Ltd. (the "Issuer"), Amendment No. 1 thereto filed by Vivo Capital, LLC and Vivo Capital VIII, LLC on July 20, 2018, Amendment No. 2 thereto filed by Vivo Capital, LLC, Vivo Capital VIII, LLC and Vivo Capital IX, LLC on August 27, 2018, Amendment No. 3 thereto filed by Vivo Capital VIII, LLC and Vivo Capital IX, LLC on March 19, 2025, and Amendment No. 4 thereto filed by Vivo Capital VIII, LLC and Vivo Capital IX, LLC on April 24, 2025 (as so amended, the "Schedule 13D"). The Items herein amend the information disclosed under the corresponding Items of the Schedule 13D as described herein. Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in the Schedule 13D.

**Item 4. Purpose of Transaction**

Item 4 is hereby supplemented and amended by adding the following:

On June 11, 2025, Vivo Capital, an affiliate of the Reporting Persons, issued a press release disclosing a letter to all Issuer shareholders (the "Letter").  The Letter addresses a number of statements in the April 29, 2025 letter from the Issuer's Board of Directors (the "Board") that Vivo Capital believes are false, and to reaffirm the Reporting Persons' commitment to upholding the best interests of all Issuer shareholders and to transparent corporate governance. The press release is attached hereto as Exhibit J and incorporated herein by reference.

The Issuer on May 19, 2025 gave notice of a Special Meeting of Shareholders to be held on July 8, 2025 following a requisition by SAIF Partners IV L.P. ("SAIF") for the purposes of (i) removing certain directors and (ii) electing certain other director nominees, including Mr. Shan Fu. The Reporting Persons will continue to engage in discussions with other shareholders regarding SAIF's proposals. The Reporting Persons intend to vote their shares in favor of such proposals at the Special Meeting.

Consistent with the above stated intentions, the Reporting Persons will seek to influence management of the Issuer or its Board of Directors with respect to the business and affairs of the Issuer and may from time to time pursue or propose actions to the Issuer, other shareholders or other persons. The Reporting Persons pursuit of such matters relate to or would result in actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, including, but not limited to, changes in the present board of directors or management of the Issuer, changes in the present capitalization or dividend policy of the issuer, changes in the Issuer's business or corporate structure, changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person, and changes that will relate to the listing of the Issuer's securities on a national securities exchange. The Reporting Persons will continue to engage in discussions with other shareholders concerning some or all of such matters, particularly about the Board and the future of the Issuer.

The filing of this Amendment shall not be construed as an admission that the Reporting Persons and their affiliates, on the one hand, and any other shareholders of the Issuer and their affiliates, on the other hand, are a group, or have agreed to act as a group with each other for purposes of Section 13(d) of the Act or for any other purpose. The Reporting Persons expressly disclaim beneficial ownership of the common shares beneficially owned by other shareholders who may also be advocating for changes to the New Board.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages to this Amendment No. 5 to Schedule 13D.

As of the date hereof, the Reporting Persons collectively beneficially own an aggregate of 5,903,000 Common Shares representing 8.2% of the outstanding Common Shares.

**(b)**
The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages to this Amendment No. 5 to Schedule 13D.

As of the date hereof, the Reporting Persons collectively beneficially own an aggregate of 5,903,000 Common Shares representing 8.2% of the outstanding Common Shares.

The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages to this Amendment No. 5 to Schedule 13D.  See also Item 5(a) above.

**(c)**
The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages to this Amendment No. 5 to Schedule 13D.

As of the date hereof, the Reporting Persons collectively beneficially own an aggregate of 5,903,000 Common Shares representing 8.2% of the outstanding Common Shares.

Except as set forth herein, the Reporting Persons have not affected any transactions in Common Shares in the past sixty days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 is hereby supplemented and amended by adding the following:

Item 6 of the Schedule 13D is hereby supplemented and amended to incorporate by reference the information set forth in Item 4 to this Amendment No. 5 to Schedule 13D.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Vivo Capital VIII, LLC

**Signature:** /s/ Dr. Frank Kung

**Name/Title:** Dr. Frank Kung, Managing Member

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Vivo Capital IX, LLC

**Signature:** /s/ Dr. Frank Kung

**Name/Title:** Dr. Frank Kung, Managing Member

**Date:** 06/13/2025